Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Ascentage Pharma Group Internat logoAscentage Pharma Group Internat

AAPG · Nasdaq · USD · Market cap $1.2B · 767 employees

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.

FAIL · Does not pass the screen
11.97 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price11.97 USD at the 20 Nov 2026 close
  • Fair valueUnder review: our model's value is 2.94x the price, above our 2.00x limit.
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-20).

Current read
Markup ?
Screened · screened 2026-11-20
  • Trend Markup
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price11.97 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-10-31Read Markup14.85-19.4% to today Distribution gives way to Markup
2026-10-11Read Distribution15.37-22.1% to today ✓Markdown gives way to Distribution
2026-10-02Read Markdown15.86-24.5% to today ✓Distribution gives way to Markdown first Markdown read since August
2026-09-19Read Distribution15.40-22.3% to today ✓Markdown gives way to Distribution after a 13% slide in 11 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Ascentage Pharma Group Internat holds its Markup at $11.97. The statistical read favours the buyers, held for 4 days.

As held on the ledger · 2026-11-20
PhaseMarkup
Quantitative stateThe statistical read favours the buyers, held for 4 days
Price at the screen$11.97
ValuationN/A trailing · -20.31 forward price to earnings
Values screenFAIL · score 70.0
Beta0.77
The Workings

Five Screens: AAPG's Results

FAIL. Debt ratio

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 49.95% Below 33% Fail
Interest-bearing cash 0.00% Below 33% Pass
Receivables 68.56% Below 49% Fail
Revenue purity 14.30% Below 5% Fail

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Ascentage Pharma Group Internat's business is in a permissible area, but its interest-bearing debt is about 50% of the company, well over the ~33% line, so it does not pass on the financial screens. Its receivables are also high.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when AAPG's ethical verdict changes

Today AAPG does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. Our model's value is 2.94x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.

Method.

The Street's Range
33.00Street low 45.50Street average 55.00Street high 11.97Price

Street: 10 covering, consensus Strong Buy. Average target +280%.

Chart
The Business, in Plain Words

China Biotech Chasing Cures Burns Cash Fast

Picture a clinical stage firm in China pushing one lead drug for tough cancers while revenue jumps 117 percent yet margins sit at minus 216 percent. Ascentage shows real pipeline movement and clears our ethical screen, yet the opportunity rating stays at none because forward earnings are deeply negative, return on equity is minus 155 percent and any moat remains unknown despite analyst targets near 48 dollars.

The double fair value gap looks tempting on the surface, but a pre profit biotech with that scale of losses rarely rewards patience once trials slip or funding needs grow. China regulatory and currency exposure add further layers that standard growth metrics do not capture.

We therefore step aside even though the science may one day deliver. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-20.3x
EPS, trailing-2.26
EPS, forward-0.65
Revenue growth+29.3%strong top-line growth
Profit margin-228.5%currently unprofitable
Return on equity-236.6%not currently earning a positive return on equity
FCF yield-78.00%
Debt to equity3.70heavy leverage: higher risk if revenue softens
Current ratio1.22adequate liquidity, worth monitoring
Beta0.77steadier than the market
Short interest, float0.00%
52-week range13.12 - 33.09
Market cap$1.2B
Employees767

AAPG-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to China and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Markup $13.01 -16.0% Entry 13
2026-11-11 Markup $15.50 +4.4% Entry 12
2026-10-31 Markup · changed $14.85 -9.1% Entry 11

The framework has shifted from distribution to markup since the last review.

2026-10-24 Distribution $16.34 +6.3% Entry 10
2026-10-11 Distribution · changed $15.37 -3.1% Entry 9

The framework has shifted from markdown to distribution since the last review.

2026-10-02 Markdown · changed $15.86 +3.0% Entry 8

The framework has shifted from distribution to markdown since the last review.

2026-09-19 Distribution · changed $15.40 -18.8% Entry 7

The framework has shifted from markdown to distribution since the last review.

2026-08-20 Markdown $18.97 +1.2% Entry 6

Ethical screening: FAIL (changed).

2026-07-20 Markdown $18.74 +6.5% Entry 5
2026-07-18 Markdown $17.60 +0.0% Entry 4

Ethical screening: PASS.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on AAPG

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in AAPG's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $21.50 -20.6% · $794 -20.6%
2 months $25.33 -32.6% · $674 -32.6%
3 months $24.22 -29.5% · $705 -29.5%
6 months $29.48 -42.1% · $579 -42.1%
1 year $29.88 -42.9% · $571 -42.9%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever AAPG does next, these words stay.

Ascentage Pharma Group Internat · AAPG · Markup · $11.97
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.